tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

RVMD Stock Latest News

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Press ReleasesRevolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
30d ago
RVMD
Ideaya Biosciences names Daniel Simon chief business officer
PremiumThe Fly
Ideaya Biosciences names Daniel Simon chief business officer
1M ago
IDYA
RVMD
Revolution Medicines price target raised to $46 from $42 at Wedbush
PremiumThe Fly
Revolution Medicines price target raised to $46 from $42 at Wedbush
2M ago
RVMD
Revolution Medicines files to sell 2.19M shares of common stock
PremiumThe Fly
Revolution Medicines files to sell 2.19M shares of common stock
2M ago
RVMD
Revolution Medicines reports Q1 EPS (70c), consensus (75c)
PremiumThe Fly
Revolution Medicines reports Q1 EPS (70c), consensus (75c)
2M ago
RVMD
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
PremiumPress ReleasesRevolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
2M ago
RVMD
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
PremiumPress Releases
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
2M ago
RVMD
Revolution Medicines price target raised to $45 from $43 at Oppenheimer
PremiumThe Fly
Revolution Medicines price target raised to $45 from $43 at Oppenheimer
3M ago
RVMD
Revolution Medicines price target raised to $46 from $36 at Needham
PremiumThe Fly
Revolution Medicines price target raised to $46 from $36 at Needham
3M ago
RVMD
Revolution Medicines upgraded to Strong Buy from Outperform at Raymond James
PremiumThe Fly
Revolution Medicines upgraded to Strong Buy from Outperform at Raymond James
3M ago
RVMD
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
PremiumPress Releases
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
3M ago
RVMD
Revolution Medicines announces publications on discovery of RMC-7977
PremiumThe Fly
Revolution Medicines announces publications on discovery of RMC-7977
3M ago
RVMD
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
PremiumPress ReleasesRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
3M ago
RVMD
Revolution Medicines to Participate in Upcoming Investor Conferences
PremiumPress Releases
Revolution Medicines to Participate in Upcoming Investor Conferences
3M ago
RVMD
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
PremiumPress Releases
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
3M ago
RVMD
Disney initiated, Foot Locker upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Disney initiated, Foot Locker upgraded: Wall Street’s top analyst calls
4M ago
D
H
Revolution Medicines initiated with an Overweight at Piper Sandler
PremiumThe Fly
Revolution Medicines initiated with an Overweight at Piper Sandler
4M ago
RVMD
Revolution Medicines price target raised to $44 from $28 at H.C. Wainwright
PremiumThe Fly
Revolution Medicines price target raised to $44 from $28 at H.C. Wainwright
4M ago
RVMD
Revolution Medicines files automatic mixed securities shelf
PremiumThe Fly
Revolution Medicines files automatic mixed securities shelf
4M ago
RVMD
Revolution Medicines price target raised to $42 from $41 at Wedbush
PremiumThe FlyRevolution Medicines price target raised to $42 from $41 at Wedbush
4M ago
RVMD
Revolution Medicines sees FY24 GAAP net loss $480M-$520M
PremiumThe Fly
Revolution Medicines sees FY24 GAAP net loss $480M-$520M
4M ago
RVMD
Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
PremiumThe Fly
Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
4M ago
RVMD

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >